Compounded GLP-1 Marketing Compliance in 2026: What Changed When the Shortage List Closed
When the FDA declared the semaglutide and tirzepatide shortages resolved, the legal basis for routine 503A compounding narrowed. Your existing compounded-GLP-1 marketing was probably written for the old posture. Here is the 2026 rewrite.
Compounded GLP-1 marketing was easier to defend during the 2023-2024 shortage years than it is in 2026. When the FDA resolved the semaglutide and tirzepatide shortages and signaled the end of the broad shortage-based compounding window, the legal posture under which most clinics were marketing compounded GLP-1 quietly shifted. A lot of clinic copy is still written for the old rules.
This post walks through the 2026 reality for compounded GLP-1 advertising: what the FDA actually said, what counts as a defensible compounding rationale now, the claim patterns that survived the shift, and the ones that did not. It is the companion to our broader GLP-1 marketing compliance overview and is focused tightly on the compounded-product layer.
What the FDA actually changed
Two pieces of public FDA action matter here. First, the FDA resolved the semaglutide and tirzepatide drug-shortage listings, which removed the broad statutory basis that 503A and 503B compounders had been using to produce these molecules at scale. Second, the agency has continued to issue warning letters and public communications targeting compounded GLP-1 marketing patterns that present compounded products as interchangeable with FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound.
Compounding of these drugs is not extinct. Patient-specific compounding under section 503A remains permissible where there is a documented clinical reason a commercially available product will not work for the individual patient. What is gone is the permission slip the shortage list provided for routine, marketed-to-the-public compounded GLP-1 programs.
Marketing patterns the FDA has flagged
- Brand-name implication. Copy that uses Wegovy, Ozempic, Mounjaro, or Zepbound to draw a prospect in, then sells a compounded product, is treated as misbranding-adjacent. The warning-letter pattern over the last 24 months is consistent on this point.
- Equivalence claims. Same-as-Ozempic, generic- version-of-Wegovy, and FDA-approved-active-ingredient phrasings imply the compounded product itself has FDA approval. A molecule and a finished drug product are not the same thing.
- Open-market positioning. Compounding under section 503A is patient-specific. Advertising compounded semaglutide directly to the general public, with online ordering and no patient-specific clinical rationale visible, looks like manufacturing-by-another-name.
- Outcome guarantees. A guarantee of 20 lbs in 60 days on a compounded product compounds the problem. See section 5 of the FTC Act on outcome substantiation; FTC has taken weight-loss outcome claims as a settled enforcement priority since the Pom Wonderful era.
- Telehealth-funnel disclaimers buried in footers. If the disclosure that a patient is being prescribed a compounded product distinct from the FDA-approved drug only appears in 10pt grey type at the bottom of the page, the disclosure has not actually been made for FTC clear-and- conspicuous purposes.
Three rewrite rules for 2026
1. Lead with what you actually dispense, by molecule
“Affordable Wegovy alternative - $299/mo with no insurance hassle.”
“Medically supervised weight management program using semaglutide compounded for the individual patient at a state-licensed compounding pharmacy. This is not FDA-approved Wegovy or Ozempic; eligibility is determined during clinical consultation.”
Why: Lead with the molecule and the compounding pathway, not the brand-name halo. The non-FDA-approved disclosure is not buried at the bottom; it is in the lead.
2. Make the patient-specific rationale visible
“Order compounded semaglutide online today - approval in minutes, shipped in 48 hours.”
“Each patient completes a clinical intake reviewed by a licensed prescriber, who decides whether a compounded GLP-1 is clinically appropriate and writes a patient-specific prescription. Compounded preparations are not interchangeable with FDA-approved drug products.”
Why: The on-demand, no-friction frame is the exact pattern FDA cites when challenging whether a 503A operation is acting as a de facto manufacturer.
3. Quote substantiation by name, or do not quote it
“Studies show our compounded GLP-1 helps patients lose up to 20% of body weight.”
“In a 2021 New England Journal of Medicine trial of FDA-approved semaglutide 2.4 mg for chronic weight management (Wilding et al., STEP 1), participants meeting BMI eligibility criteria experienced an average weight reduction over 68 weeks. Individual outcomes on compounded preparations are not the same data set and will vary.”
Why: The Pom Wonderful FTC standard requires that cited evidence actually support the specific product claim. Borrowing branded-drug clinical trial data to support a compounded product overclaims; if you cite a trial, you have to name it and qualify it.
Program page checklist
- Lead headline names the molecule, not the brand.
- A how-this-program-works section describes the consultation, eligibility screening, prescription basis, and follow-up cadence.
- A what-you-are-getting section explicitly states the product is compounded, by whom, and clarifies that it is not FDA-approved Wegovy or Ozempic.
- Any cited clinical evidence is named (study, year, journal) and the population/duration is disclosed.
- Outcomes language describes ranges from named trials, not guarantees, and includes a clear individual-variation disclosure.
- Risk and side-effect information is present and accessible, not hidden behind an expand-on-click element on mobile.
Adjacent rules to know
Many compounded GLP-1 programs sit inside a broader men’s health or hormone clinic that also offers testosterone services. The marketing rules for TRT for men’s health share several patterns with compounded GLP-1 work, particularly around outcome substantiation and on-demand prescribing optics.
Built for this exact problem
Scan your clinic's content before regulators do.
RegenCompliance checks every word of your marketing against live FDA and FTC enforcement data - and rewrites violations automatically. A 30-second scan can save a $50,000–$5M regulatory response.
Weekly compliance brief
One email a week. New enforcement actions, rule changes, and tactical fixes. No spam, unsubscribe anytime.
Keep reading
Ketamine Clinic Marketing Compliance Guide: IV Ketamine for Depression Without Triggering an FDA Letter
Most ketamine clinic marketing problems are not exotic - they are six or seven repeated phrases that the FDA October 2023 communication and 2024 enforcement actions have already singled out. This guide focuses on the IV ketamine for depression use case and rewrites the patterns that get clinics in trouble.
Read articleNAD+ IV Therapy Marketing and the FDA Position: What Actually Has Approval, What Does Not, and How to Word It
Most NAD+ IV therapy marketing trouble is upstream of the FTC longevity-claim issue. It is the quiet implication that NAD+ has some kind of FDA status it does not have. Here is the actual FDA position and how to word a NAD+ program page around it.
Read articleOzone Therapy Marketing Compliance Rules: The FDA Position on Medical Ozone and the Phrases That Trigger Action
The FDA has stated publicly that ozone is a toxic gas with no known useful medical application. That position is the entire frame for ozone therapy marketing. Most ozone clinic copy is written as if the FDA is silent on the topic - it is not.
Read article